Immutep Limited (NASDAQ: IMMP), an innovative player in the biotechnology sector, is capturing the attention of investors with its ambitious focus on developing immunotherapies for cancer and autoimmune diseases. The company’s lead product, eftilagimod alfa, is at the forefront of this endeavor, representing a promising advancement in the fight against cancer.

**Company and Market Overview**

Headquartered in Sydney, Australia, Immutep operates within the healthcare sector, specializing in biotechnology. With a market capitalization of $410.67 million, the company is a significant player in the biopharmaceutical landscape. Immutep’s current stock price is $2.79, which remains stable with no recent price change, and it has…